<DOC>
	<DOCNO>NCT00000751</DOCNO>
	<brief_summary>To evaluate effect anti-HIV immune serum globulin ( HIVIG ) versus immune globulin ( IVIG ) administer pregnancy newborn , combination zidovudine ( AZT ) administer intrapartum newborn , incidence HIV infection infant bear HIV-infected woman receive AZT pregnancy medical indication . Vertical transmission HIV mother child may occur , , parturition ( via breast-feeding ) . It believe therapy administer pregnancy intrapartum may help prevent vertical transmission . Additionally , adjunctive short-term antiretroviral therapy newborn , follow intensive viral exposure presume occur birth , may necessary .</brief_summary>
	<brief_title>A Phase III Randomized , Double-Blind , Controlled Study Use Anti-HIV Immune Serum Globulin ( HIVIG ) Prevention Maternal-Fetal HIV Transmission Pregnant Women Newborns Receiving Zidovudine ( AZT )</brief_title>
	<detailed_description>Vertical transmission HIV mother child may occur , , parturition ( via breast-feeding ) . It believe therapy administer pregnancy intrapartum may help prevent vertical transmission . Additionally , adjunctive short-term antiretroviral therapy newborn , follow intensive viral exposure presume occur birth , may necessary . Pregnant woman currently receive AZT randomize 20-30 week gestation begin receive either HIVIG IVIG every 28 day delivery . Within 12 hour birth , infant receives infusion match study drug . During labor , woman receive intravenous load dose AZT administer 1 hour , follow continuous infusion intrapartum period umbilical cord clamp . All infant receive AZT syrup every 6 hour , begin soon oral fluid tolerate within 8-12 hour birth continue 6 week . Women follow 26 week postpartum . Infants follow week 1 , 2 , 4 , every 4 week week 24 , every 12 week week 60 , week 78 ( 18 month ) , week 104 ( 24 month ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immune Sera</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Women Medications require obstetrical management HIV infection ( e.g. , acyclovir , ketoconazole , isoniazid , antibiotic , antiretroviral therapy intolerant fail AZT ) , unless specifically exclude . Infants Drug treatment sign drug withdrawal ( phenobarbital , chlorpromazine , tincture opium , paregoric Valium ) . Infants Medications indicate management HIVexposed infant ( e.g. , hepatitis B vaccine , syphilis treatment , Pneumocystis carinii pneumonia prophylaxis ) . Patients must : Documented HIV infection . Been receive AZT current pregnancy medical indication . Gestational age 20 30 week . Intention carry pregnancy term . Available venous access ( placement central line Hickman catheter indicate study purpose ) . Willingness follow participate site study duration . NOTE : Father fetus ( available reasonable attempt contact ) must also provide informed consent . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Illness associate excessive protein loss , e.g. , severe proteinuria ( protein &gt; = 4 g protein 24hour urine collection ) . Patients follow prior condition exclude : Evidence preexist fetal anomaly ( e.g. , anencephaly , renal agenesis , Potter 's syndrome ) may result high probability fetusinfant would survive end study period . Chorionic villus sampling ( CVS ) percutaneous umbilical blood sampling ( PUBS ) occur pregnancy prior study entry . Illness associate excessive protein loss , e.g. , chronic diarrhea document weight gain 3month period pregnancy . Preexisting condition hypogammaglobulinemia immune thrombocytopenia felt require IVIG therapy . Prior Medication : Excluded : Receipt antiHIV vaccine passive immunotherapy HIVIG IVIG pregnancy prior study entry . Receipt antiretroviral agent AZT pregnancy prior study entry ( e.g. , rCD4 , CD4IgG , d4T , ddC , ddI ) .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Immunoglobulins , Intravenous</keyword>
	<keyword>Immunization , Passive</keyword>
</DOC>